SCHEMBL6085071

SCHEMBL6085071

Cc1ccc2oc(-c3c[nH]nc3-c3ccc(NC(=O)C(C)c4ccc(Cl)cc4)cc3)nc2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 3/20 0.52
SENP7 Q9BQF6 2/20 0.52
AGPAT2 O15120 6/20 0.49
NPC1 O15118 3/20 0.49
RAB9A P51151 3/20 0.49
ALDH1A1 P00352 2/20 0.49
HPGD P15428 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
HSD17B10 Q99714 2/20 0.49
KDM4E B2RXH2 1/20 0.49
MAPK1 P28482 1/20 0.49
TP53 P04637 1/20 0.48
GAA P10253 1/20 0.48
THRB P10828 1/20 0.48
TSHR P16473 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
MAPT P10636 1/20 0.47
MAOA P21397 1/20 0.47
ADRA1A P35348 1/20 0.47
CETP P11597 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6085509 0.88 SMN1; SMN2 (0.63) CASP3SENP7AGPAT2NPC1RAB9A
SCHEMBL6086812 0.87 CETP (0.50) CASP3SENP7NPC1RAB9AALDH1A1
SCHEMBL6084737 0.84 TP53 (0.64) ALDH1A1HPGDSMN1; SMN2HSD17B10KDM4E
SCHEMBL6085124 0.83 CASP3 (0.61) CASP3SENP7AGPAT2NPC1RAB9A
SCHEMBL6085581 0.82 MMP2 (0.52) AGPAT2NPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL6086585 0.82 MAPT (0.58) NPC1RAB9AALDH1A1HPGDSMN1; SMN2
SCHEMBL6085936 0.81 CETP (0.55) CASP3SENP7AGPAT2NPC1RAB9A
SCHEMBL6086280 0.81 KDM4E (0.45) CASP3SENP7NPC1RAB9AALDH1A1
SCHEMBL6085949 0.80 AGPAT2 (0.66) AGPAT2NPC1RAB9AALDH1A1HPGD
SCHEMBL6086731 0.79 AGPAT2 (0.56) AGPAT2NPC1RAB9AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US claimed
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 CASP3 889/4885SENP7 2374/4885AGPAT2 3284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.